NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NYSE · GSK · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
GSK plc’s quoted price sits in the lower half of its reported 52-week range, 21.1% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
GSK plc’s forward annual dividend is $1.80 per share, paid quarterly. The forward yield is 3.7% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
GSK plc’s next earnings report is currently expected on Feb 3, 2027, with estimated earnings per share of $0.77. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow GSK plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:14 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Jul 30, 2025 |
| $1.23+9.82% vs estimate |
| $10.61B+1.12% vs estimate |
| Q1 2025 | Apr 30, 2025 | $1.13+4.63% vs estimate | $10.04B+3.33% vs estimate |
|---|
| Q4 2024 | Feb 5, 2025 | $0.59+34.09% vs estimate | $10.16B+6.53% vs estimate |
|---|
THE ANALYST VIEW
29 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $57.95.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$146.33+$5.40 (+3.83%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.75% below the high.
CHF 401.70+CHF 2.90 (+0.73%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.67% below the high.
$161.10+$5.02 (+3.22%)
Novartis AG’s quoted price sits in the upper half of its reported 52-week range, 5.49% below the high.
$174.40+$4.89 (+2.88%)
AstraZeneca PLC’s quoted price sits in the lower half of its reported 52-week range, 18.01% below the high.
$460.73+$8.90 (+1.97%)
Amgen Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.61% below the high.
$39.14+$0.85 (+2.22%)
Novo Nordisk A/S’s quoted price sits in the lower half of its reported 52-week range, 39.0% below the high.
